PIP
CMMB

Philadelphia Investment Partners’s Chemomab Therapeutics CMMB Stock Holding History

Philadelphia Investment Partners’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$24.3K Buy
15,000
+6,800
+83% +$11.5K 0.02% 116
2026
Q1 		$12.9K Buy
+8,200
New +$14K 0.01% 126

Other funds holding CMMB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Lido Advisors
Lido Advisors Los Angeles, California $36.8B AUM 26.6% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Philadelphia Investment Partners's CMMB Position: Q2 2026 in Review

Philadelphia Investment Partners increased its Chemomab Therapeutics (CMMB) stake by 83% in Q2 2026, buying an estimated $11.5K and bringing the position to 15,000 shares worth $24.3K. The position accounts for 0.02% of the portfolio, ranked #116.

Philadelphia Investment Partners first reported a position in CMMB in Q1 2026 and has held it in 2 quarters since. 13 funds tracked by Wall St. Rank hold CMMB as of Q2 2026.

  • Philadelphia Investment Partners held 15,000 shares of Chemomab Therapeutics worth $24.3K as of Q2 2026.
  • Philadelphia Investment Partners bought 6,800 Chemomab Therapeutics shares in Q2 2026, an estimated $11.5K.
  • Chemomab Therapeutics made up 0.02% of Philadelphia Investment Partners's portfolio in Q2 2026, its #116 holding.
  • Philadelphia Investment Partners first reported a position in Chemomab Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 13 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2026.

Based on Philadelphia Investment Partners's 13F filing for Q2 2026, filed 14 Aug 2026.